Table 2.
Drug Interactions Between Direct-acting Antivirals and Antiretroviral Drugs—Preferred Regimens
Green indicates coadministration is safe; yellow indicates a dose change or additional monitoring is warranted; and pink indicates the combination should be avoided.
Abbreviation: ND, no data.
aCaution only with tenofovir disoproxil fumarate.
bIncrease in tenofovir depends on which additional concomitant antiretroviral agents are administered.
cAvoid tenofovir disoproxil fumarate in patients with an estimated glomerular filtration rate <60 mL/min; tenofovir concentrations may exceed those with established renal safety data in individuals on ritonavir- or cobicistat-containing regimens.
dStudied as part of fixed-dose combinations with ledipasvir/sofosbuvir or sofosbuvir/velpatasvir plus TAF, emtricitabine, elvitegravir, and cobicistat.
